Shanghai BDgene Technology completed a $9 million Series A round to develop its mRNA delivery platform, a viroid-like particle delivery system of mRNA. BDgene, a clinical stage company, uses the technology to deliver CRISPR/Cas9 mRNA, which provides ...

Featured Events:

ChinaBio® Partnering Forum 2021
May 10–14, 2021
ChinaBio® Partnering Forum, in its new hybrid delivery, will be held in-person for the first two days in Shanghai, China followed by three days of virtual partnering, program sessions, company presentations and showcases, networking opportunities and much more. New event experience. Renowned content and partnering opportunities.
Apply to Present and get your company on the opportunity map by showcasing your breakthroughs in a recorded pitch to an audience of VCs and potential partners at the 2021 event.

ChinaBio® Daily Update

Contents


BDgene Completes $9 Million Round for CRISPR/Cas9 mRNA Candidates

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Shanghai BDgene Technology completed a $9 million Series A round to develop its mRNA delivery platform, a viroid-like particle delivery system of mRNA. BDgene, a clinical stage company, uses the technology to deliver CRISPR/Cas9 mRNA, which provides safe and controllable gene editing in vivo, according to the company. BDgene's lead product is BD111, a CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy administered via corneal injection in patients with refractory herpetic viral keratitis, which has been approved for a six patient clinical trial in China. More details....

Share this with colleagues:

     
 

Innovent Reports Positive Data from Phase III Tyvyt Trial in NSCLC

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Innovent Biologics of Suzhou reported positive data from a Phase III trial of its anti-PD-1 drug, Tyvyt®, as a second line therapy for patients with non-small cell lung cancer. Patients who received Tyvyt® experienced a statistically significant improvement in overall survival compared to those who received docetaxel. Currently, Innovent has three Tyvyt® NDAs under review in China. In addition, the company is conducting more than 20 clinical trials of Tyvyt® in a variety of cancer indications. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

     
 

LintonPharm Starts China Trial of Candidate for Bladder Cancer

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

LintonPharm, a Guangzhou biopharma, was approved to start a China Phase I/II clinical trial of catumaxomab to treat recurrent Non-Muscle-Invasive Bladder Cancer (NMIBC). The trial will enroll patients whose tumors have recurred due to Bacillus Calmette-Guerin (BCG) vaccine failure. In 2020, LintonPharm started a China Phase III trial of catumaxomab. an immunotherapy, in patients with advanced gastric cancer. LintonPharm develops innovative T cell engaging bispecific antibodies, aiming to turn malignant cancers into manageable or curable diseases. More details....

Share this with colleagues:

     
 

Junshi's PD-1 Approved for Third Indication in China, Bladder Cancer

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Shanghai Junshi Bio announced China's NMPA approved a third indication for the company's PD-1 drug. Toripalimab is now approved as a second-line therapy for locally advanced or metastatic urothelial carcinoma in patients who failed platinum-based chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum chemotherapy. Previously, toripalimab was approved as a second-line treatment for metastatic melanoma and a third-line therapy for nasopharyngeal carcinoma. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues:

     
 

Gracell Reports Positive Data from Trial of Off-the Shelf CAR-T Candidate

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Gracell Biotech, a Suzhou cell therapy company, reported positive results from a China Phase I trial of its allogeneic CAR-T candidate. GC027 targets CD7. It was administered to adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) who had previously been treated with a median of six therapies. A single infusion of GC027 at one of three dosing levels produced a complete remission in all six patients. In the future, Gracell plans to test GC027 in global markets for T-All and other cancers as well. More details...

Stock Symbol: (NDQQ: GRCL)

Share this with colleagues:

     
 

More Recent Articles

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.


Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

Greg B. Scott
Executive Editor
ChinaBio® Today


ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC


 


Safely Unsubscribe ArchivesPreferencesContactSubscribePrivacy